New immune therapy shows promise for Long-Term disease control
NCT ID NCT06076642
First seen Apr 09, 2026 · Last updated May 16, 2026 · Updated 5 times
Summary
This study tests the long-term safety of TAK-881, an immunoglobulin infusion, in adults and children with primary immunodeficiency diseases (PIDD). Participants, who must have completed a prior study, receive regular infusions every 2 to 4 weeks. The goal is to see if the treatment is safe and well-tolerated over time, helping control infections and manage the condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNODEFICIENCY DISEASES (PID) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aarhus Universitetshospital
Aarhus, 8200, Denmark
-
Allergy & Asthma Clinical Research
Walnut Creek, California, 94598, United States
-
Allergy Partners of North Texas
Dallas, Texas, 75230, United States
-
Allergy, Asthma and Immunology Center
Tulsa, Oklahoma, 74136, United States
-
Central Georgia Infectious Disease Consultants
Macon, Georgia, 31201, United States
-
Duke Asthma, Allergy and Airway Center
Durham, North Carolina, 27705, United States
-
Fakultni nemocnice Motol a Homolka Ustav imunologie
Prague, 150 06, Czechia
-
General Hospital of Thessaloniki
Thessaloniki, 56429, Greece
-
Hospital Sant Joan de Deu Barcelona
Barcelona, 08950, Spain
-
Instytut Pomnik - Centrum Zdrowia Dziecka
Warsaw, 04-730, Poland
-
Klinika Deti a Dorastu - Odborne Ambulancie UNM a JLF UK
Martin, 036 01, Slovakia
-
Louisiana State University Health Science Center
New Orleans, Louisiana, 70118, United States
-
Montefiore Medical Center
The Bronx, New York, 10461, United States
-
NUDCH (National Institute of Childrens Diseases)
Bratislava, 833 40, Slovakia
-
National Jewish Medical And Research Center
Denver, Colorado, 80206-2761, United States
-
North Shore-Long Island Jewish Health Systems
Great Neck, New York, 11021, United States
-
OKIA s.r.o
Košice, 040 01, Slovakia
-
Osrodek Pediatryczny im. DR J. Korczaka, Wojewodzkie
Lodz, 90329, Poland
-
Rush University Medical Center-Allergy/ Immunology Center
Chicago, Illinois, 60612-3852, United States
-
Sneeze, Wheeze, & Itch Associates, LLC
Normal, Illinois, 61761, United States
-
University Hospital Brno
Brno, 62500, Czechia
-
University of California, Irvine Medical Sciences I
Irvine, California, 92697, United States
-
University of South Florida
St. Petersburg, Florida, 33701, United States
-
Uniwersyteckie Centrum Kliniczne (UCK)
Gdansk, 80-952, Poland
-
Wojskowy Instytut Medyczny Panstwowy Instytut
Warsaw, 04-141, Poland
Conditions
Explore the condition pages connected to this study.